A Phase 2, single-arm, open-label study to evaluate the safety and efficacy of MGTA-456 in patients with sickle cell disease (SCD) undergoing hematopoietic stem cell transplantation (HSCT)

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.